A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort.
Journal
Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
27
10
2021
received:
27
07
2021
accepted:
08
12
2021
pubmed:
18
12
2021
medline:
22
6
2022
entrez:
17
12
2021
Statut:
ppublish
Résumé
Mixed cryoglobulinemia is the most common HCV extrahepatic manifestation. We aimed to prospectively evaluate the cryoglobulinemic vasculitis (CV) clinical profile after a sustained virologic response (SVR) over a medium-term to long-term period. Direct-acting antiviral-treated cryoglobulinemic patients, consecutively enrolled in the multicentric Italian Platform for the Study of Viral Hepatitis Therapy cohort, were prospectively evaluated. Cumulative incidence Kaplan-Meier curves were reported for response, clinical deterioration, relapse and relapse-free survival rates. Cox regression analysis evaluated factors associated with different outcomes. A clinical response was reported in at least one follow-up point for 373 of 423 (88%) patients with CV who achieved SVR. Clinical response increased over time with a 76% improvement rate at month 12 after the end of treatment. A full complete response (FCR) was reached by 164 (38.8%) patients in at least one follow-up point. CV clinical response fluctuated, with some deterioration of the initial response in 49.6% of patients (median time of deterioration, 19 months). In patients who achieved FCR and had an available follow-up (137 patients) a relapse was observed in 13% and it was transient in 66.7% of patients. The rate of patients without any deterioration was 58% and 41% at 12 and 24 months, respectively. After achieving SVR, a clinical nonresponse was associated with older age and renal involvement; a clinical deterioration/relapse was associated with high pretreatment rheumatoid factor values, and FCR was inversely associated with age, neuropathy, and high cryocrit levels. In patients with CV, HCV eradication may not correspond to a persistent clinical improvement, and clinical response may fluctuate. This implies an attentive approach to post-SVR evaluation through prognostic factors and tailored treatment.
Sections du résumé
BACKGROUND AND AIMS
Mixed cryoglobulinemia is the most common HCV extrahepatic manifestation. We aimed to prospectively evaluate the cryoglobulinemic vasculitis (CV) clinical profile after a sustained virologic response (SVR) over a medium-term to long-term period.
APPROACH AND RESULTS
Direct-acting antiviral-treated cryoglobulinemic patients, consecutively enrolled in the multicentric Italian Platform for the Study of Viral Hepatitis Therapy cohort, were prospectively evaluated. Cumulative incidence Kaplan-Meier curves were reported for response, clinical deterioration, relapse and relapse-free survival rates. Cox regression analysis evaluated factors associated with different outcomes. A clinical response was reported in at least one follow-up point for 373 of 423 (88%) patients with CV who achieved SVR. Clinical response increased over time with a 76% improvement rate at month 12 after the end of treatment. A full complete response (FCR) was reached by 164 (38.8%) patients in at least one follow-up point. CV clinical response fluctuated, with some deterioration of the initial response in 49.6% of patients (median time of deterioration, 19 months). In patients who achieved FCR and had an available follow-up (137 patients) a relapse was observed in 13% and it was transient in 66.7% of patients. The rate of patients without any deterioration was 58% and 41% at 12 and 24 months, respectively. After achieving SVR, a clinical nonresponse was associated with older age and renal involvement; a clinical deterioration/relapse was associated with high pretreatment rheumatoid factor values, and FCR was inversely associated with age, neuropathy, and high cryocrit levels.
CONCLUSION
In patients with CV, HCV eradication may not correspond to a persistent clinical improvement, and clinical response may fluctuate. This implies an attentive approach to post-SVR evaluation through prognostic factors and tailored treatment.
Identifiants
pubmed: 34919289
doi: 10.1002/hep.32281
pmc: PMC9305531
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
220-232Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.
Références
PLoS One. 2017 Oct 4;12(10):e0185728
pubmed: 28977040
Clin Dev Immunol. 2012;2012:980942
pubmed: 22852020
Lancet. 2012 Jan 28;379(9813):348-60
pubmed: 21868085
Liver Int. 2018 Jan;38(1):183
pubmed: 28599083
N Engl J Med. 2021 Mar 18;384(11):1038-1052
pubmed: 33730456
Clin Exp Rheumatol. 2017 Mar-Apr;35 Suppl 103(1):67-76
pubmed: 28466806
Am J Med. 1966 Jun;40(6):837-56
pubmed: 4956871
Clin Gastroenterol Hepatol. 2019 Feb;17(3):518-526
pubmed: 29857143
Joint Bone Spine. 2019 Nov;86(6):707-713
pubmed: 30731128
Ann Rheum Dis. 2011 Jul;70(7):1183-90
pubmed: 21571735
Blood. 2003 Aug 1;102(3):996-9
pubmed: 12714514
Eur J Gastroenterol Hepatol. 2018 Oct;30(10):1208-1215
pubmed: 30138160
Hepatology. 2022 Jul;76(1):220-232
pubmed: 34919289
Arthritis Res Ther. 2017 Apr 8;19(1):74
pubmed: 28388935
Hepatology. 2017 May;65(5):1770-1771
pubmed: 27943361
Gastroenterology. 2017 Jul;153(1):49-52.e5
pubmed: 28288791
Am J Gastroenterol. 2017 Aug;112(8):1298-1308
pubmed: 28291241
Nat Rev Dis Primers. 2018 Aug 2;4(1):11
pubmed: 30072738
Hepatology. 2002 Oct;36(4 Pt 1):978-85
pubmed: 12297847
Aliment Pharmacol Ther. 2018 Aug;48(4):440-450
pubmed: 29952013
Rheumatology (Oxford). 2016 Nov;55(11):2084-2085
pubmed: 27338085
Gastroenterology. 2018 Aug;155(2):311-315.e6
pubmed: 29705529
Br J Haematol. 2020 Dec;191(5):775-783
pubmed: 32790920
Rheumatology (Oxford). 2014 Dec;53(12):2209-13
pubmed: 24994905
Ann Rheum Dis. 2016 Oct;75(10):1777-82
pubmed: 26567178
Hepatology. 2016 Nov;64(5):1473-1482
pubmed: 27483451
Dig Liver Dis. 2015 Sep;47(9):741-3
pubmed: 26138800
Rheumatology (Oxford). 2018 Oct 1;57(10):1870-1871
pubmed: 29868896
J Hepatol. 2009 Jan;50(1):59-68
pubmed: 19013661
Clin Gastroenterol Hepatol. 2017 Apr;15(4):575-583.e1
pubmed: 27725289
Clin Exp Rheumatol. 2018 Mar-Apr;36 Suppl 111(2):161-162
pubmed: 29185964
Eur Rev Med Pharmacol Sci. 2018 Sep;22(18):6057-6062
pubmed: 30280791
Hepatology. 2021 Sep;74(3):1164-1173
pubmed: 33721342
Br J Haematol. 1994 Oct;88(2):392-4
pubmed: 7803287
Mediterr J Hematol Infect Dis. 2017 Jan 01;9(1):e2017007
pubmed: 28101312
Semin Arthritis Rheum. 2020 Aug;50(4):695-700
pubmed: 32521323
J Rheumatol. 1996 Sep;23(9):1641-3
pubmed: 8877939
Hepatology. 2015 Apr;61(4):1145-53
pubmed: 25431357
Liver Int. 2019 Apr;39(4):628-632
pubmed: 30690862
J Transl Med. 2014 Jan 24;12:21
pubmed: 24456582
Autoimmun Rev. 2016 Dec;15(12):1145-1160
pubmed: 27640316
Autoimmun Rev. 2017 May;16(5):523-541
pubmed: 28286108
Arch Virol. 1997;142(3):545-55
pubmed: 9349300
Autoimmun Rev. 2011 Jun;10(8):444-54
pubmed: 21303705